Figures & data
Figure 1. Hazard ratio of moderate or severe COPD exacerbation and of severe pneumonia comparing single-inhaler triple therapy with single-inhaler LAMA-LABA dual bronchodilators in COPD patients with a history of multiple exacerbations, in the first year after treatment initiation, stratified by the presence of type 2 diabetes comorbidity.
Data sharing statement
This study is based in part on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The data are provided by patients and collected by the UK National Health Service as part of their care and support. Because electronic health records are classified as “sensitive data” by the UK Data Protection Act, information governance restrictions (to protect patient confidentiality) prevent data sharing via public deposition. Data are available with approval through the individual constituent entities controlling access to the data. Specifically, the primary care data can be requested via application to the Clinical Practice Research Datalink (https://www.cprd.com).